Home / Market News / $TPUS

$TPUS news and market catalysts

The 3 most recent market catalysts affecting $TPUS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

3 catalysts 1 high impact 2 bullish 0 bearish Pharmaceuticals
Nov 18, 2026 Corporate Catalyst Bullish Impact 65
AstraZeneca and Tempus AI Extend Strategic Services Agreement Through 2031
AstraZeneca and Tempus AI have extended their master services agreement, originally from 2021, through December 31, 2031. This extension includes a significant financial commitment…
Oct 29, 2026 Corporate Catalyst Neutral Impact 55
Tempus AI Director Eric P. Lefkofsky Reports Sale of 250,000 Shares
Tempus AI director Eric P. Lefkofsky sold a substantial block of 250,000 shares, totaling $17.59 million. While insider sales can sometimes signal a lack of confidence, this could …
Aug 19, 2026 Corporate Catalyst Bullish Impact 85
Shares of Tempus AI are trading higher amid possible sympathy with Merck and Moderna after the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint. The results may also boost sentiment around Tempus AI’s planned $1.5 billion acquisition of Personalis, whose genomic tumor-profiling technology supports the personalized vaccine used in the trial.
The successful Phase 3 trial for Merck and Moderna's personalized vaccine is a major positive for the biotechnology sector, particularly for companies involved in genomic profiling…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.